Transcriptional Addiction in Cancer

Cell

Volumn 168, Issue 4, 2017, Pages 629-643

  Bradner, James E ^a   Hnisz, Denes ^b   Young, Richard A ^b,c  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^b WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH   (United States)

^c MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIS ACTING ELEMENT; TRANSCRIPTION FACTOR;

CANCER CELL; CANCER GENETICS; CANCER THERAPY; CHROMOSOME; GENE TARGETING; GENETIC DISORDER; HOMEOSTASIS; HUMAN; MALIGNANT NEOPLASM; PRIORITY JOURNAL; REVIEW; TARGET TISSUE; TRANSCRIPTION REGULATION; ANIMAL; DNA METHYLATION; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETIC TRANSCRIPTION; GENETICS; METABOLISM; NEOPLASMS; PATHOLOGY;

ANIMALS; DNA METHYLATION; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HOMEOSTASIS; HUMANS; NEOPLASMS; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC;

EID: 85012194101     PISSN: 00928674     EISSN: 10974172     Source Type: Journal    
DOI: 10.1016/j.cell.2016.12.013     Document Type: Review

References (140)

1. Affer, M., Chesi, M., Chen, W.D., Keats, J.J., Demchenko, Y.N., Tamizhmani, K., Garbitt, V.M., Riggs, D.L., Brents, L.A., Roschke, A.V., et al. Promiscuous MYC locus rearrangements hijack enhancers but mostly super-enhancers to dysregulate MYC expression in multiple myeloma. Leukemia 28 (2014), 1725–1735.
2. Alarcón, C., Zaromytidou, A.I., Xi, Q., Gao, S., Yu, J., Fujisawa, S., Barlas, A., Miller, A.N., Manova-Todorova, K., Macias, M.J., et al. Nuclear CDKs drive Smad transcriptional activation and turnover in BMP and TGF-beta pathways. Cell 139 (2009), 757–769.
3. Allen, B.L., Taatjes, D.J., The Mediator complex: a central integrator of transcription. Nat. Rev. Mol. Cell Biol. 16 (2015), 155–166.
4. Amabile, A., Migliara, A., Capasso, P., Biffi, M., Cittaro, D., Naldini, L., Lombardo, A., Inheritable Silencing of Endogenous Genes by Hit-and-Run Targeted Epigenetic Editing. Cell 167 (2016), 219–232.
5. Barbieri, C.E., Baca, S.C., Lawrence, M.S., Demichelis, F., Blattner, M., Theurillat, J.P., White, T.A., Stojanov, P., Van Allen, E., Stransky, N., et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat. Genet. 44 (2012), 685–689.
6. Baubec, T., Ivánek, R., Lienert, F., Schübeler, D., Methylation-dependent and -independent genomic targeting principles of the MBD protein family. Cell 153 (2013), 480–492.
7. Beroukhim, R., Mermel, C.H., Porter, D., Wei, G., Raychaudhuri, S., Donovan, J., Barretina, J., Boehm, J.S., Dobson, J., Urashima, M., et al. The landscape of somatic copy-number alteration across human cancers. Nature 463 (2010), 899–905.
8. Bhagwat, A.S., Roe, J.S., Mok, B.Y., Hohmann, A.F., Shi, J., Vakoc, C.R., BET Bromodomain Inhibition Releases the Mediator Complex from Select cis-Regulatory Elements. Cell Rep. 15 (2016), 519–530.
9. Bhagwat, A.S., Vakoc, C.R., Targeting Transcription Factors in Cancer. Trends Cancer 1 (2015), 53–65.
10. Bisgrove, D.A., Mahmoudi, T., Henklein, P., Verdin, E., Conserved P-TEFb-interacting domain of BRD4 inhibits HIV transcription. Proc. Natl. Acad. Sci. USA 104 (2007), 13690–13695.
11. Brown, J.D., Lin, C.Y., Duan, Q., Griffin, G., Federation, A.J., Paranal, R.M., Bair, S., Newton, G., Lichtman, A.H., Kung, A.L., et al. NF-κB directs dynamic super enhancer formation in inflammation and atherogenesis. Mol. Cell 56 (2014), 219–231.
12. Buganim, Y., Faddah, D.A., Jaenisch, R., Mechanisms and models of somatic cell reprogramming. Nat. Rev. Genet. 14 (2013), 427–439.
13. Bulger, M., Groudine, M., Functional and mechanistic diversity of distal transcription enhancers. Cell 144 (2011), 327–339.
14. Bywater, M.J., Pearson, R.B., McArthur, G.A., Hannan, R.D., Dysregulation of the basal RNA polymerase transcription apparatus in cancer. Nat. Rev. Cancer 13 (2013), 299–314.
15. Cai, S.F., Chen, C.W., Armstrong, S.A., Drugging Chromatin in Cancer: Recent Advances and Novel Approaches. Mol. Cell 60 (2015), 561–570.
16. Campos, E.I., Reinberg, D., Histones: annotating chromatin. Annu. Rev. Genet. 43 (2009), 559–599.
17. Chapuy, B., McKeown, M.R., Lin, C.Y., Monti, S., Roemer, M.G., Qi, J., Rahl, P.B., Sun, H.H., Yeda, K.T., Doench, J.G., et al. Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphoma. Cancer Cell 24 (2013), 777–790.
18. Chen, C.W., Armstrong, S.A., Targeting DOT1L and HOX gene expression in MLL-rearranged leukemia and beyond. Exp. Hematol. 43 (2015), 673–684.
19. Chen, Z., Brand, N.J., Chen, A., Chen, S.J., Tong, J.H., Wang, Z.Y., Waxman, S., Zelent, A., Fusion between a novel Krüppel-like zinc finger gene and the retinoic acid receptor-alpha locus due to a variant t(11;17) translocation associated with acute promyelocytic leukaemia. EMBO J. 12 (1993), 1161–1167.
20. Chipumuro, E., Marco, E., Christensen, C.L., Kwiatkowski, N., Zhang, T., Hatheway, C.M., Abraham, B.J., Sharma, B., Yeung, C., Altabef, A., et al. CDK7 inhibition suppresses super-enhancer-linked oncogenic transcription in MYCN-driven cancer. Cell 159 (2014), 1126–1139.
21. Christensen, C.L., Kwiatkowski, N., Abraham, B.J., Carretero, J., Al-Shahrour, F., Zhang, T., Chipumuro, E., Herter-Sprie, G.S., Akbay, E.A., Altabef, A., et al. Targeting transcriptional addictions in small cell lung cancer with a covalent CDK7 inhibitor. Cancer Cell 26 (2014), 909–922.
22. Clark, V.E., Harmancı, A.S., Bai, H., Youngblood, M.W., Lee, T.I., Baranoski, J.F., Ercan-Sencicek, A.G., Abraham, B.J., Weintraub, A.S., Hnisz, D., et al. Recurrent somatic mutations in POLR2A define a distinct subset of meningiomas. Nat. Genet. 48 (2016), 1253–1259.
23. Daigle, S.R., Olhava, E.J., Therkelsen, C.A., Basavapathruni, A., Jin, L., Boriack-Sjodin, P.A., Allain, C.J., Klaus, C.R., Raimondi, A., Scott, M.P., et al. Potent inhibition of DOT1L as treatment of MLL-fusion leukemia. Blood 122 (2013), 1017–1025.
24. Darnell, J.E. Jr., Transcription factors as targets for cancer therapy. Nat. Rev. Cancer 2 (2002), 740–749.
25. Dawson, M.A., Prinjha, R.K., Dittmann, A., Giotopoulos, G., Bantscheff, M., Chan, W.I., Robson, S.C., Chung, C.W., Hopf, C., Savitski, M.M., et al. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature 478 (2011), 529–533.
26. Delmore, J.E., Issa, G.C., Lemieux, M.E., Rahl, P.B., Shi, J., Jacobs, H.M., Kastritis, E., Gilpatrick, T., Paranal, R.M., Qi, J., et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 146 (2011), 904–917.
27. Deshpande, A.J., Chen, L., Fazio, M., Sinha, A.U., Bernt, K.M., Banka, D., Dias, S., Chang, J., Olhava, E.J., Daigle, S.R., et al. Leukemic transformation by the MLL-AF6 fusion oncogene requires the H3K79 methyltransferase Dot1l. Blood 121 (2013), 2533–2541.
28. Doudna, J.A., Charpentier, E., Genome editing. The new frontier of genome engineering with CRISPR-Cas9. Science, 346, 2014, 1258096.
29. Dowen, J.M., Fan, Z.P., Hnisz, D., Ren, G., Abraham, B.J., Zhang, L.N., Weintraub, A.S., Schuijers, J., Lee, T.I., Zhao, K., Young, R.A., Control of cell identity genes occurs in insulated neighborhoods in mammalian chromosomes. Cell 159 (2014), 374–387.
30. Drier, Y., Cotton, M.J., Williamson, K.E., Gillespie, S.M., Ryan, R.J., Kluk, M.J., Carey, C.D., Rodig, S.J., Sholl, L.M., Afrogheh, A.H., et al. An oncogenic MYB feedback loop drives alternate cell fates in adenoid cystic carcinoma. Nat. Genet. 48 (2016), 265–272.
31. Eick, D., Geyer, M., The RNA polymerase II carboxy-terminal domain (CTD) code. Chem. Rev. 113 (2013), 8456–8490.
32. ENCODE Project Consortium. An integrated encyclopedia of DNA elements in the human genome. Nature 489 (2012), 57–74.
33. Felsher, D.W., Bishop, J.M., Reversible tumorigenesis by MYC in hematopoietic lineages. Mol. Cell 4 (1999), 199–207.
34. Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., Smith, W.B., Fedorov, O., Morse, E.M., Keates, T., Hickman, T.T., Felletar, I., et al. Selective inhibition of BET bromodomains. Nature 468 (2010), 1067–1073.
35. Flavahan, W.A., Drier, Y., Liau, B.B., Gillespie, S.M., Venteicher, A.S., Stemmer-Rachamimov, A.O., Suvà, M.L., Bernstein, B.E., Insulator dysfunction and oncogene activation in IDH mutant gliomas. Nature 529 (2016), 110–114.
36. Fong, C.Y., Gilan, O., Lam, E.Y., Rubin, A.F., Ftouni, S., Tyler, D., Stanley, K., Sinha, D., Yeh, P., Morison, J., et al. BET inhibitor resistance emerges from leukaemia stem cells. Nature 525 (2015), 538–542.
37. Garraway, L.A., Lander, E.S., Lessons from the cancer genome. Cell 153 (2013), 17–37.
38. Geng, F., Wenzel, S., Tansey, W.P., Ubiquitin and proteasomes in transcription. Annu. Rev. Biochem. 81 (2012), 177–201.
39. Ghirlando, R., Felsenfeld, G., CTCF: making the right connections. Genes Dev. 30 (2016), 881–891.
40. Gibcus, J.H., Dekker, J., The hierarchy of the 3D genome. Mol. Cell 49 (2013), 773–782.
41. Gorkin, D.U., Leung, D., Ren, B., The 3D genome in transcriptional regulation and pluripotency. Cell Stem Cell 14 (2014), 762–775.
42. Graf, T., Enver, T., Forcing cells to change lineages. Nature 462 (2009), 587–594.
43. Gröschel, S., Sanders, M.A., Hoogenboezem, R., de Wit, E., Bouwman, B.A., Erpelinck, C., van der Velden, V.H., Havermans, M., Avellino, R., van Lom, K., et al. A single oncogenic enhancer rearrangement causes concomitant EVI1 and GATA2 deregulation in leukemia. Cell 157 (2014), 369–381.
44. Guenther, M.G., Lawton, L.N., Rozovskaia, T., Frampton, G.M., Levine, S.S., Volkert, T.L., Croce, C.M., Nakamura, T., Canaani, E., Young, R.A., Aberrant chromatin at genes encoding stem cell regulators in human mixed-lineage leukemia. Genes Dev. 22 (2008), 3403–3408.
45. Hah, N., Benner, C., Chong, L.W., Yu, R.T., Downes, M., Evans, R.M., Inflammation-sensitive super enhancers form domains of coordinately regulated enhancer RNAs. Proc. Natl. Acad. Sci. USA 112 (2015), E297–E302.
46. Hay, D., Hughes, J.R., Babbs, C., Davies, J.O., Graham, B.J., Hanssen, L.L., Kassouf, M.T., Oudelaar, A.M., Sharpe, J.A., Suciu, M.C., et al. Genetic dissection of the α-globin super-enhancer in vivo. Nat. Genet. 48 (2016), 895–903.
47. Hnisz, D., Abraham, B.J., Lee, T.I., Lau, A., Saint-André, V., Sigova, A.A., Hoke, H.A., Young, R.A., Super-enhancers in the control of cell identity and disease. Cell 155 (2013), 934–947.
48. Hnisz, D., Schuijers, J., Lin, C.Y., Weintraub, A.S., Abraham, B.J., Lee, T.I., Bradner, J.E., Young, R.A., Convergence of developmental and oncogenic signaling pathways at transcriptional super-enhancers. Mol. Cell 58 (2015), 362–370.
49. Hnisz, D., Day, D.S., Young, R.A., Insulated Neighborhoods: Structural and Functional Units of Mammalian Gene Control. Cell 167 (2016), 1188–1200.
50. Hnisz, D., Weintraub, A.S., Day, D.S., Valton, A.L., Bak, R.O., Li, C.H., Goldmann, J., Lajoie, B.R., Fan, Z.P., Sigova, A.A., et al. Activation of proto-oncogenes by disruption of chromosome neighborhoods. Science 351 (2016), 1454–1458.
51. Huang, M.E., Ye, Y.C., Chen, S.R., Chai, J.R., Lu, J.X., Zhoa, L., Gu, L.J., Wang, Z.Y., Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 72 (1988), 567–572.
52. Inaba, H., Pui, C.H., Glucocorticoid use in acute lymphoblastic leukaemia. Lancet Oncol. 11 (2010), 1096–1106.
53. Jain, M., Arvanitis, C., Chu, K., Dewey, W., Leonhardt, E., Trinh, M., Sundberg, C.D., Bishop, J.M., Felsher, D.W., Sustained loss of a neoplastic phenotype by brief inactivation of MYC. Science 297 (2002), 102–104.
54. Ji, X., Dadon, D.B., Powell, B.E., Fan, Z.P., Borges-Rivera, D., Shachar, S., Weintraub, A.S., Hnisz, D., Pegoraro, G., Lee, T.I., et al. 3D Chromosome Regulatory Landscape of Human Pluripotent Cells. Cell Stem Cell 18 (2016), 262–275.
55. Jiang, T., Raviram, R., Snetkova, V., Rocha, P.P., Proudhon, C., Badri, S., Bonneau, R., Skok, J.A., Kluger, Y., Identification of multi-loci hubs from 4C-seq demonstrates the functional importance of simultaneous interactions. Nucleic Acids Res. 44 (2016), 8714–8725.
56. Jones, P.A., Issa, J.P., Baylin, S., Targeting the cancer epigenome for therapy. Nat. Rev. Genet. 17 (2016), 630–641.
57. Jonkers, I., Lis, J.T., Getting up to speed with transcription elongation by RNA polymerase II. Nat. Rev. Mol. Cell Biol. 16 (2015), 167–177.
58. Joo, J.Y., Schaukowitch, K., Farbiak, L., Kilaru, G., Kim, T.K., Stimulus-specific combinatorial functionality of neuronal c-fos enhancers. Nat. Neurosci. 19 (2016), 75–83.
59. Kadoch, C., Crabtree, G.R., Mammalian SWI/SNF chromatin remodeling complexes and cancer: Mechanistic insights gained from human genomics. Sci. Adv., 1, 2015, e1500447.
60. Kagey, M.H., Newman, J.J., Bilodeau, S., Zhan, Y., Orlando, D.A., van Berkum, N.L., Ebmeier, C.C., Goossens, J., Rahl, P.B., Levine, S.S., et al. Mediator and cohesin connect gene expression and chromatin architecture. Nature 467 (2010), 430–435.
61. Kandoth, C., McLellan, M.D., Vandin, F., Ye, K., Niu, B., Lu, C., Xie, M., Zhang, Q., McMichael, J.F., Wyczalkowski, M.A., et al. Mutational landscape and significance across 12 major cancer types. Nature 502 (2013), 333–339.
62. Katainen, R., Dave, K., Pitkänen, E., Palin, K., Kivioja, T., Välimäki, N., Gylfe, A.E., Ristolainen, H., Hänninen, U.A., Cajuso, T., et al. CTCF/cohesin-binding sites are frequently mutated in cancer. Nat. Genet. 47 (2015), 818–821.
63. Kennedy, A.L., Vallurupalli, M., Chen, L., Crompton, B., Cowley, G., Vazquez, F., Weir, B.A., Tsherniak, A., Parasuraman, S., Kim, S., et al. Functional, chemical genomic, and super-enhancer screening identify sensitivity to cyclin D1/CDK4 pathway inhibition in Ewing sarcoma. Oncotarget 6 (2015), 30178–30193.
64. Kieffer-Kwon, K.R., Tang, Z., Mathe, E., Qian, J., Sung, M.H., Li, G., Resch, W., Baek, S., Pruett, N., Grøntved, L., et al. Interactome maps of mouse gene regulatory domains reveal basic principles of transcriptional regulation. Cell 155 (2013), 1507–1520.
65. Kouzarides, T., Chromatin modifications and their function. Cell 128 (2007), 693–705.
66. Krivtsov, A.V., Feng, Z., Lemieux, M.E., Faber, J., Vempati, S., Sinha, A.U., Xia, X., Jesneck, J., Bracken, A.P., Silverman, L.B., et al. H3K79 methylation profiles define murine and human MLL-AF4 leukemias. Cancer Cell 14 (2008), 355–368.
67. Roadmap Epigenomics Consortium, Kundaje, A., Meuleman, W., Ernst, J., Bilenky, M., Yen, A., Heravi-Moussavi, A., Kheradpour, P., Zhang, Z., Wang, J., Ziller, M.J., et al. Integrative analysis of 111 reference human epigenomes. Nature 518 (2015), 317–330.
68. Kwiatkowski, N., Zhang, T., Rahl, P.B., Abraham, B.J., Reddy, J., Ficarro, S.B., Dastur, A., Amzallag, A., Ramaswamy, S., Tesar, B., et al. Targeting transcription regulation in cancer with a covalent CDK7 inhibitor. Nature 511 (2014), 616–620.
69. Lai, F., Orom, U.A., Cesaroni, M., Beringer, M., Taatjes, D.J., Blobel, G.A., Shiekhattar, R., Activating RNAs associate with Mediator to enhance chromatin architecture and transcription. Nature 494 (2013), 497–501.
70. Lane, D., Levine, A., p53 Research: the past thirty years and the next thirty years. Cold Spring Harb. Perspect. Biol., 2, 2010, a000893.
71. Lawrence, M.S., Stojanov, P., Mermel, C.H., Robinson, J.T., Garraway, L.A., Golub, T.R., Meyerson, M., Gabriel, S.B., Lander, E.S., Getz, G., Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 505 (2014), 495–501.
72. Lee, T.I., Young, R.A., Transcriptional regulation and its misregulation in disease. Cell 152 (2013), 1237–1251.
73. Levine, M., Cattoglio, C., Tjian, R., Looping back to leap forward: transcription enters a new era. Cell 157 (2014), 13–25.
74. Li, W., Notani, D., Rosenfeld, M.G., Enhancers as non-coding RNA transcription units: recent insights and future perspectives. Nat. Rev. Genet. 17 (2016), 207–223.
75. Lin, C.Y., Lovén, J., Rahl, P.B., Paranal, R.M., Burge, C.B., Bradner, J.E., Lee, T.I., Young, R.A., Transcriptional amplification in tumor cells with elevated c-Myc. Cell 151 (2012), 56–67.
76. Lin, C.Y., Erkek, S., Tong, Y., Yin, L., Federation, A.J., Zapatka, M., Haldipur, P., Kawauchi, D., Risch, T., Warnatz, H.J., et al. Active medulloblastoma enhancers reveal subgroup-specific cellular origins. Nature 530 (2016), 57–62.
77. Liu, M.Y., DeNizio, J.E., Schutsky, E.K., Kohli, R.M., The expanding scope and impact of epigenetic cytosine modifications. Curr. Opin. Chem. Biol. 33 (2016), 67–73.
78. Liu, X.S., Wu, H., Ji, X., Stelzer, Y., Wu, X., Czauderna, S., Shu, J., Dadon, D., Young, R.A., Jaenisch, R., Editing DNA Methylation in the Mammalian Genome. Cell 167 (2016), 233–247.
79. Lo-Coco, F., Avvisati, G., Vignetti, M., Thiede, C., Orlando, S.M., Iacobelli, S., Ferrara, F., Fazi, P., Cicconi, L., Di Bona, E., et al. Gruppo Italiano Malattie Ematologiche dell'Adulto German-Austrian Acute Myeloid Leukemia Study Group, Study Alliance Leukemia. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N. Engl. J. Med. 369 (2013), 111–121.
80. Long, H.K., Prescott, S.L., Wysocka, J., Ever-Changing Landscapes: Transcriptional Enhancers in Development and Evolution. Cell 167 (2016), 1170–1187.
81. Lovén, J., Hoke, H.A., Lin, C.Y., Lau, A., Orlando, D.A., Vakoc, C.R., Bradner, J.E., Lee, T.I., Young, R.A., Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell 153 (2013), 320–334.
82. Mäkinen, N., Mehine, M., Tolvanen, J., Kaasinen, E., Li, Y., Lehtonen, H.J., Gentile, M., Yan, J., Enge, M., Taipale, M., et al. MED12, the mediator complex subunit 12 gene, is mutated at high frequency in uterine leiomyomas. Science 334 (2011), 252–255.
83. Malik, S., Roeder, R.G., The metazoan Mediator co-activator complex as an integrative hub for transcriptional regulation. Nat. Rev. Genet. 11 (2010), 761–772.
84. Mansour, M.R., Abraham, B.J., Anders, L., Berezovskaya, A., Gutierrez, A., Durbin, A.D., Etchin, J., Lawton, L., Sallan, S.E., Silverman, L.B., et al. Oncogene regulation. An oncogenic super-enhancer formed through somatic mutation of a noncoding intergenic element. Science 346 (2014), 1373–1377.
85. Mellén, M., Ayata, P., Dewell, S., Kriaucionis, S., Heintz, N., MeCP2 binds to 5hmC enriched within active genes and accessible chromatin in the nervous system. Cell 151 (2012), 1417–1430.
86. Moellering, R.E., Cornejo, M., Davis, T.N., Del Bianco, C., Aster, J.C., Blacklow, S.C., Kung, A.L., Gilliland, D.G., Verdine, G.L., Bradner, J.E., Direct inhibition of the NOTCH transcription factor complex. Nature 462 (2009), 182–188.
87. Morris, S.A., Daley, G.Q., A blueprint for engineering cell fate: current technologies to reprogram cell identity. Cell Res. 23 (2013), 33–48.
88. Mullen, A.C., Orlando, D.A., Newman, J.J., Lovén, J., Kumar, R.M., Bilodeau, S., Reddy, J., Guenther, M.G., DeKoter, R.P., Young, R.A., Master transcription factors determine cell-type-specific responses to TGF-β signaling. Cell 147 (2011), 565–576.
89. Nabet, B., Ó Broin, P., Reyes, J.M., Shieh, K., Lin, C.Y., Will, C.M., Popovic, R., Ezponda, T., Bradner, J.E., Golden, A.A., Licht, J.D., Deregulation of the Ras-Erk Signaling Axis Modulates the Enhancer Landscape. Cell Rep. 12 (2015), 1300–1313.
90. Nie, Z., Hu, G., Wei, G., Cui, K., Yamane, A., Resch, W., Wang, R., Green, D.R., Tessarollo, L., Casellas, R., et al. c-Myc is a universal amplifier of expressed genes in lymphocytes and embryonic stem cells. Cell 151 (2012), 68–79.
91. Northcott, P.A., Lee, C., Zichner, T., Stütz, A.M., Erkek, S., Kawauchi, D., Shih, D.J., Hovestadt, V., Zapatka, M., Sturm, D., et al. Enhancer hijacking activates GFI1 family oncogenes in medulloblastoma. Nature 511 (2014), 428–434.
92. Ong, C.T., Corces, V.G., Enhancer function: new insights into the regulation of tissue-specific gene expression. Nat. Rev. Genet. 12 (2011), 283–293.
93. Pagliarini, R., Shao, W., Sellers, W.R., Oncogene addiction: pathways of therapeutic response, resistance, and road maps toward a cure. EMBO Rep. 16 (2015), 280–296.
94. Patel, A.P., Tirosh, I., Trombetta, J.J., Shalek, A.K., Gillespie, S.M., Wakimoto, H., Cahill, D.P., Nahed, B.V., Curry, W.T., Martuza, R.L., et al. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science 344 (2014), 1396–1401.
95. Pelish, H.E., Liau, B.B., Nitulescu, I.I., Tangpeerachaikul, A., Poss, Z.C., Da Silva, D.H., Caruso, B.T., Arefolov, A., Fadeyi, O., Christie, A.L., et al. Mediator kinase inhibition further activates super-enhancer-associated genes in AML. Nature 526 (2015), 273–276.
96. Phillips-Cremins, J.E., Corces, V.G., Chromatin insulators: linking genome organization to cellular function. Mol. Cell 50 (2013), 461–474.
97. Piunti, A., Shilatifard, A., Epigenetic balance of gene expression by Polycomb and COMPASS families. Science, 352, 2016, aad9780.
98. Puissant, A., Frumm, S.M., Alexe, G., Bassil, C.F., Qi, J., Chanthery, Y.H., Nekritz, E.A., Zeid, R., Gustafson, W.C., Greninger, P., et al. Targeting MYCN in neuroblastoma by BET bromodomain inhibition. Cancer Discov. 3 (2013), 308–323.
99. Rahl, P.B., Lin, C.Y., Seila, A.C., Flynn, R.A., McCuine, S., Burge, C.B., Sharp, P.A., Young, R.A., c-Myc regulates transcriptional pause release. Cell 141 (2010), 432–445.
100. Rathert, P., Roth, M., Neumann, T., Muerdter, F., Roe, J.S., Muhar, M., Deswal, S., Cerny-Reiterer, S., Peter, B., Jude, J., et al. Transcriptional plasticity promotes primary and acquired resistance to BET inhibition. Nature 525 (2015), 543–547.
101. Rowley, J.D., Golomb, H.M., Dougherty, C., 15/17 translocation, a consistent chromosomal change in acute promyelocytic leukaemia. Lancet 1 (1977), 549–550.
102. Sancho-Martinez, I., Baek, S.H., Izpisua Belmonte, J.C., Lineage conversion methodologies meet the reprogramming toolbox. Nat. Cell Biol. 14 (2012), 892–899.
103. Sanda, T., Lawton, L.N., Barrasa, M.I., Fan, Z.P., Kohlhammer, H., Gutierrez, A., Ma, W., Tatarek, J., Ahn, Y., Kelliher, M.A., et al. Core transcriptional regulatory circuit controlled by the TAL1 complex in human T cell acute lymphoblastic leukemia. Cancer Cell 22 (2012), 209–221.
104. Sharma, S.V., Lee, D.Y., Li, B., Quinlan, M.P., Takahashi, F., Maheswaran, S., McDermott, U., Azizian, N., Zou, L., Fischbach, M.A., et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 141 (2010), 69–80.
105. Shi, J., Vakoc, C.R., The mechanisms behind the therapeutic activity of BET bromodomain inhibition. Mol. Cell 54 (2014), 728–736.
106. Shi, J., Whyte, W.A., Zepeda-Mendoza, C.J., Milazzo, J.P., Shen, C., Roe, J.S., Minder, J.L., Mercan, F., Wang, E., Eckersley-Maslin, M.A., et al. Role of SWI/SNF in acute leukemia maintenance and enhancer-mediated Myc regulation. Genes Dev. 27 (2013), 2648–2662.
107. Shin, H.Y., Willi, M., Yoo, K.H., Zeng, X., Wang, C., Metser, G., Hennighausen, L., Hierarchy within the mammary STAT5-driven Wap super-enhancer. Nat. Genet. 48 (2016), 904–911.
108. Shu, S., Lin, C.Y., He, H.H., Witwicki, R.M., Tabassum, D.P., Roberts, J.M., Janiszewska, M., Huh, S.J., Liang, Y., Ryan, J., et al. Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer. Nature 529 (2016), 413–417.
109. Soshnev, A.A., Josefowicz, S.Z., Allis, C.D., Greater Than the Sum of Parts: Complexity of the Dynamic Epigenome. Mol. Cell 62 (2016), 681–694.
110. Soucek, L., Whitfield, J., Martins, C.P., Finch, A.J., Murphy, D.J., Sodir, N.M., Karnezis, A.N., Swigart, L.B., Nasi, S., Evan, G.I., Modelling Myc inhibition as a cancer therapy. Nature 455 (2008), 679–683.
111. Soucek, L., Whitfield, J.R., Sodir, N.M., Massó-Vallés, D., Serrano, E., Karnezis, A.N., Swigart, L.B., Evan, G.I., Inhibition of Myc family proteins eradicates KRas-driven lung cancer in mice. Genes Dev. 27 (2013), 504–513.
112. Spitz, F., Furlong, E.E., Transcription factors: from enhancer binding to developmental control. Nat. Rev. Genet. 13 (2012), 613–626.
113. Stathis, A., Zucca, E., Bekradda, M., Gomez-Roca, C., Delord, J.P., de La Motte Rouge, T., Uro-Coste, E., de Braud, F., Pelosi, G., French, C.A., Clinical Response of Carcinomas Harboring the BRD4-NUT Oncoprotein to the Targeted Bromodomain Inhibitor OTX015/MK-8628. Cancer Discov. 6 (2016), 492–500.
114. Stratton, M.R., Campbell, P.J., Futreal, P.A., The cancer genome. Nature 458 (2009), 719–724.
115. Stuart, D., Sellers, W.R., Linking somatic genetic alterations in cancer to therapeutics. Curr. Opin. Cell Biol. 21 (2009), 304–310.
116. Sur, I., Taipale, J., The role of enhancers in cancer. Nat. Rev. Cancer 16 (2016), 483–493.
117. Taub, R., Kirsch, I., Morton, C., Lenoir, G., Swan, D., Tronick, S., Aaronson, S., Leder, P., Translocation of the c-myc gene into the immunoglobulin heavy chain locus in human Burkitt lymphoma and murine plasmacytoma cells. Proc. Natl. Acad. Sci. USA 79 (1982), 7837–7841.
118. Taylor, S.M., Jones, P.A., Multiple new phenotypes induced in 10T1/2 and 3T3 cells treated with 5-azacytidine. Cell 17 (1979), 771–779.
119. Tessarz, P., Kouzarides, T., Histone core modifications regulating nucleosome structure and dynamics. Nat. Rev. Mol. Cell Biol. 15 (2014), 703–708.
120. Thomas, D., Tyers, M., Transcriptional regulation: Kamikaze activators. Curr. Biol. 10 (2000), R341–R343.
121. Tomazou, E.M., Sheffield, N.C., Schmidl, C., Schuster, M., Schönegger, A., Datlinger, P., Kubicek, S., Bock, C., Kovar, H., Epigenome mapping reveals distinct modes of gene regulation and widespread enhancer reprogramming by the oncogenic fusion protein EWS-FLI1. Cell Rep. 10 (2015), 1082–1095.
122. Trompouki, E., Bowman, T.V., Lawton, L.N., Fan, Z.P., Wu, D.C., DiBiase, A., Martin, C.S., Cech, J.N., Sessa, A.K., Leblanc, J.L., et al. Lineage regulators direct BMP and Wnt pathways to cell-specific programs during differentiation and regeneration. Cell 147 (2011), 577–589.
123. Vaquerizas, J.M., Kummerfeld, S.K., Teichmann, S.A., Luscombe, N.M., A census of human transcription factors: function, expression and evolution. Nat. Rev. Genet. 10 (2009), 252–263.
124. Vierbuchen, T., Wernig, M., Molecular roadblocks for cellular reprogramming. Mol. Cell 47 (2012), 827–838.
125. Viny, A.D., Ott, C.J., Spitzer, B., Rivas, M., Meydan, C., Papalexi, E., Yelin, D., Shank, K., Reyes, J., Chiu, A., et al. Dose-dependent role of the cohesin complex in normal and malignant hematopoiesis. J. Exp. Med. 212 (2015), 1819–1832.
126. Vogelstein, B., Papadopoulos, N., Velculescu, V.E., Zhou, S., Diaz, L.A. Jr., Kinzler, K.W., Cancer genome landscapes. Science 339 (2013), 1546–1558.
127. Walker, B.A., Wardell, C.P., Brioli, A., Boyle, E., Kaiser, M.F., Begum, D.B., Dahir, N.B., Johnson, D.C., Ross, F.M., Davies, F.E., Morgan, G.J., Translocations at 8q24 juxtapose MYC with genes that harbor superenhancers resulting in overexpression and poor prognosis in myeloma patients. Blood Cancer J., 4, 2014, e191.
128. Wang, Z.Y., Chen, Z., Acute promyelocytic leukemia: from highly fatal to highly curable. Blood 111 (2008), 2505–2515.
129. Wang, Y., Zhang, T., Kwiatkowski, N., Abraham, B.J., Lee, T.I., Xie, S., Yuzugullu, H., Von, T., Li, H., Lin, Z., et al. CDK7-dependent transcriptional addiction in triple-negative breast cancer. Cell 163 (2015), 174–186.
130. Watson, I.R., Takahashi, K., Futreal, P.A., Chin, L., Emerging patterns of somatic mutations in cancer. Nat. Rev. Genet. 14 (2013), 703–718.
131. Weinstein, I.B., Joe, A.K., Mechanisms of disease: Oncogene addiction-a rationale for molecular targeting in cancer therapy. Nat. Clin. Pract. Oncol. 3 (2006), 448–457.
132. Whyte, W.A., Orlando, D.A., Hnisz, D., Abraham, B.J., Lin, C.Y., Kagey, M.H., Rahl, P.B., Lee, T.I., Young, R.A., Master transcription factors and mediator establish super-enhancers at key cell identity genes. Cell 153 (2013), 307–319.
133. Winter, G.E., Buckley, D.L., Paulk, J., Roberts, J.M., Souza, A., Dhe-Paganon, S., Bradner, J.E., DRUG DEVELOPMENT. Phthalimide conjugation as a strategy for in vivo target protein degradation. Science 348 (2015), 1376–1381.
134. Yamanaka, S., Induced pluripotent stem cells: past, present, and future. Cell Stem Cell 10 (2012), 678–684.
135. Yang, H., Schramek, D., Adam, R.C., Keyes, B.E., Wang, P., Zheng, D., Fuchs, E., ETS family transcriptional regulators drive chromatin dynamics and malignancy in squamous cell carcinomas. eLife, 4, 2015, e10870.
136. Yashiro-Ohtani, Y., Wang, H., Zang, C., Arnett, K.L., Bailis, W., Ho, Y., Knoechel, B., Lanauze, C., Louis, L., Forsyth, K.S., et al. Long-range enhancer activity determines Myc sensitivity to Notch inhibitors in T cell leukemia. Proc. Natl. Acad. Sci. USA 111 (2014), E4946–E4953.
137. Zhang, T., Kwiatkowski, N., Olson, C.M., Dixon-Clarke, S.E., Abraham, B.J., Greifenberg, A.K., Ficarro, S.B., Elkins, J.M., Liang, Y., Hannett, N.M., et al. Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors. Nat. Chem. Biol. 12 (2016), 876–884.
138. Zhang, X., Choi, P.S., Francis, J.M., Imielinski, M., Watanabe, H., Cherniack, A.D., Meyerson, M., Identification of focally amplified lineage-specific super-enhancers in human epithelial cancers. Nat. Genet. 48 (2016), 176–182.
139. Ziller, M.J., Gu, H., Müller, F., Donaghey, J., Tsai, L.T., Kohlbacher, O., De Jager, P.L., Rosen, E.D., Bennett, D.A., Bernstein, B.E., et al. Charting a dynamic DNA methylation landscape of the human genome. Nature 500 (2013), 477–481.
140. Zuber, J., Shi, J., Wang, E., Rappaport, A.R., Herrmann, H., Sison, E.A., Magoon, D., Qi, J., Blatt, K., Wunderlich, M., et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 478 (2011), 524–528.